About Temprian

Kettil Cedercreutz

PhD, CEO

Kettil Cedercreutz PhD, CEO holds extensive service as Professor, Associate Provost and Dean at the University of Cincinnati at the intersection of academia and industry. Cedercreutz holds a MSc degree in Industrial Economics and Manufacturing Engineering from the top Engineering School in Finland. His PhD focuses on statistical analysis of assessment data. Cedercreutz has a solid background in market-oriented development of products and services. Kettil.Cedercreutz@TemprianTherapeutics.com (513) 374 1180

Caroline Le Poole

PhD, CSO

Caroline Le Poole, PhD, CSO is a Professor of Dermatology, Microbiology and Immunology at the Northwestern Feinberg School of Medicine with decades of experience in Investigative Dermatology and Immunology research. She earned her PhD at the University of Amsterdam. Professor Le Poole has held numerous NIH grants focusing on various aspects of immunotherapy. Professor Le Poole earned her PhD at the University of Amsterdam. She is the lead inventor of the HSP70i based therapy, Caroline.LePoole@TemprianTherapeutics.com

Mukesh Kumar

PhD, RAC, DABRM

Dr. Mukesh Kumar, PhD, RAC, DABRM, Director of Regulatory Affairs holds a 25+ years of experience in regulatory affairs and quality assurance for the development and manufacture of pharmaceutical and biotech products. Dr. Kumar has been involved in excess of 100 multi-national clinical trials, filing numerous submissions with the US Food and Drug Administration (FDA). Dr. Kumar authors a popular Weekly Newsletter on FDA related issues subscribed by more than 100,000 readers worldwide. Dr. Kumar is certified as a regulatory affairs professional by the Regulatory Affairs Professional Society, USA. His PhD is in Biochemistry.

Paul Burton

JD, MBA, CFO

Paul Burton, Chief Financial Officer has 19 years of experience in corporate finance, running small businesses, and working for firms such as Citigroup Corporate & Investment Bank and GE Capital. Paul Burton is a serial entrepreneur, with a track record of retargeting drugs for the pharmaceutical market. His background includes serving as a U.S. Regular Army Commissioned Officer (Infantry, First Lieutenant) and currently serves as an Entrepreneur in Residence at Northwestern University. Paul Burton is in charge of organizing fundraising campaigns for Temprian. Paul@TemprianTherapeutics.com (847) 322 7971

John D. Nieland

PhD, VP of Strategy

John D. Nieland holds an in-depth research background in immunology, biopharmaceuticals and clinical trials. In addition to his scientific experience John is a founder of three biotech companies. As director of research at Medigene AG John was involved in the development of the AAV-HPV vaccine. He is the former vice president of preclinical research at Borean Pharma. John is the inventor on15 patents, including several on the AAV vaccine platform. At Temprian John’s responsibilities include the development of the Temprian Therapeutics portfolio.